Overview

A Phase 3 Trial of Epcoritamab in R/R DLBCL

Status:
Recruiting

Trial end date:
2024-05-01

Target enrollment:

Participant gender:

Summary

This is an open-label, randomized (1:1), multi-center trial of epcoritamab (GEN3013; DuoBody®-CD3xCD20) versus prespecified investigator's choice of chemotherapy in patients with relapsed, refractory diffuse large B-Cell Lymphoma

Phase:

Phase 3

Details

Lead Sponsor:

Genmab

Collaborator:

AbbVie